Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy

Journal of Neurology

Volumn 259, Issue 4, 2012, Pages 712-719

  Hashizume, Atsushi ^a   Katsuno, Masahisa ^a   Banno, Haruhiko ^a,b   Suzuki, Keisuke ^a   Suga, Noriaki ^a   Tanaka, Fumiaki ^a   Sobue, Gen ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

Clinical trial; Natural history; Negative expectation; Placebo effect; Spinal and bulbar muscular atrophy

Indexed keywords

PLACEBO;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS ASSESSMENT QUESTIONNAIRE 5; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; KENNEDY DISEASE; MALE; MODIFIED QUANTITATIVE MYASTHENIA GRAVIS; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PLACEBO EFFECT; PRIORITY JOURNAL; RATING SCALE; REVISED AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCALE; SAMPLE SIZE; WALKING;

ADULT; AGED; BULBO-SPINAL ATROPHY, X-LINKED; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PLACEBO EFFECT; PSYCHOMOTOR PERFORMANCE; QUESTIONNAIRES; TREATMENT OUTCOME; WALKING;

EID: 84862530394     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-6251-2     Document Type: Article

References (33)

1. Kennedy WR, Alter M, Sung JH (1968) Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 18:671-680
2. Sperfeld AD, Karitzky J, Brummer D et al (2002) X-linked bulbospinal neuronopathy: Kennedy disease. Arch Neurol 59:1921-1926 (Pubitemid 35424651)
3. Sobue G, Hashizume Y, Mukai E, Hirayama M, Mitsuma T, Takahashi A (1989) X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 112(Pt 1):209-232 (Pubitemid 19056483)
4. Atsuta N, Watanabe H, Ito M et al (2006) Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain 129(Pt 6):1446-1455 (Pubitemid 43999377)
5. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352:77-79 (Pubitemid 21896702)
6. Fischbeck KH (1997) Kennedy disease. J Inherit Metab Dis 20:152-158 (Pubitemid 27273478)
7. La Spada AR, Taylor JP (2010) Repeat expansion disease: progress and puzzles in disease pathogenesis. Nat Rev Genet 11:247-258
8. Sobue G, Doyu M, Kachi T et al (1993) Subclinical phenotypic expressions in heterozygous females of X-linked recessive bulbospinal neuronopathy. J Neurol Sci 117:74-78 (Pubitemid 23274652)
9. Schmidt BJ, Greenberg CR, Allingham-Hawkins DJ, Spriggs EL (2002) Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology 59:770-772
10. Katsuno M, Adachi H, Kume A et al (2002) Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35:843-854
11. Katsuno M, Adachi H, Doyu M et al (2003) Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 9:768-773 (Pubitemid 36749228)
12. Takeyama K, Ito S, Yamamoto A et al (2002) Androgendependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 35:855-864
13. Chevalier-Larsen ES, O'Brien CJ, Wang H et al (2004) Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci 24:4778-4786 (Pubitemid 38668202)
14. Banno H, Adachi H, Katsuno M et al (2006) Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin: a pathogenic marker. Ann Neurol 59:520-526 (Pubitemid 43358073)
15. Banno H, Katsuno M, Suzuki K et al (2009) Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol 65:140-150
16. Katsuno M, Banno H, Suzuki K et al (2010) Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:875-884
17. Hróbjartsson A, Gøtzsche PC (2001) Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 344:1594-1602 (Pubitemid 32479913)
18. Diederich NJ, Goetz CG (2008) The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies. Neurology 71:677-684
19. The ALS (1996) CNTF treatment study (ACTS) phase I-II study group. The amyotrophic lateral sclerosis functional rating scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol 53:141-147
20. Ohashi Y, Tashiro K, Itoyama Y et al (2001) Study of functional rating scale for amyotrophic lateral sclerosis: revised ALSFRS (ALSFRS-R) Japanese version. No To Shinkei 53:346-355 (Pubitemid 33757007)
21. Jenkinson C, Fitzpatrick R, Brennan C, Bromberg M, Swash M (1999) Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neurone disease: the ALSAQ-40. J Neurol 246(Suppl 3):III16-III21
22. Jenkinson C, Fitzpatrick R (2001) Reduced item set for the amyotrophic lateral sclerosis assessment questionnaire: development and validation of the ALSAQ-5. J Neurol Neurosurg Psychiatry 70:70-73 (Pubitemid 32096123)
23. Yamaguchi T, Ohbu S, Saito M et al (2004) Validity and clinical applicability of the Japanese version of amyotrophic lateral sclerosis-assessment questionnaire 40 (ALSAQ-40). No To Shinkei 56:483-494 (Pubitemid 39044873)
24. Besinger UA, Toyka KV, Hömberg M et al (1983) Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 33:1316-1321 (Pubitemid 13021194)
25. Takeuchi Y, Katsuno M, Banno H et al (2008) Walking capacity evaluated by the 6-minute walk test in spinal and bulbar muscular atrophy. Muscle Nerve 38:964-971
26. Montes J, McDermott MP, Martens WB et al (2010) Six-minute walk test demonstrates motor fatigue in spinal muscular atrophy. Neurology 74:833-838
27. Savci S, Inal-Ince D, Arikan H et al (2005) Six-minute walk distance as a measure of functional exercise capacity in multiple sclerosis. Disabil Rehabil 27:1365-1371
28. Doyu M, Sobue G, Mukai E, Kachi T, Yasuda T, Mitsuma T, Takahashi A (1992) Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Ann Neurol 32:707-710
29. Rascol O (2009) "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design. Neurology 72:S51-S58
30. de Carvalho M, Pinto S, Costa J, Evangelista T, Ohana B, Pinto A (2010) A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 11:456-460
31. Pascuzzi RM, Shefner J, Chappell AS et al (2010) A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 11:266-271
32. Gordon PH, Moore DH, Miller RG et al (2007) Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 6:1045-1053 (Pubitemid 350116691)
33. Pollo A, Benedetti F (2009) The placebo response: neurobiological and clinical issues of neurological relevance. Prog Brain Res 175:283-294